ClinicalTrials.gg
RecruitingNCT07134153INOVATEUpdated Oct 26, 2026

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases

A Phase 1/2 interventional study of T-DXd in Breast Cancer, sponsored by Fudan University. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Fudan University · Phase 1/2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 26, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
139
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing trastuzumab deruxtecan in Breast Neoplasms — 32 open to participants now, 46 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Planned enrollment
29th of 59
139 · median 138
Started
2025
with 10 others
Phase 1/2
4 of 59
2 open now
Primary completion
2027-01
later than 15 of 45 live
Registered
44th of 59
by date
Lead sponsor
4 of 59
Fudan University

Among the 59 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 29th largest by planned enrollment, is one of 11 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 15 of the 45 other live ones, and was the 44th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 59 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

Multiple trials confirm systemic T-DXd efficacy in HER2+ breast cancer with leptomeningeal/brain metastases, yet median LM survival remains 3-4 months, highlighting unmet needs. While systemic therapies improve survival, intracranial disease control remains limited due to poor BBB penetration. Preclinical data show no detectable T-DXd/DXd in CSF, though intrathecal trastuzumab demonstrates preliminary safety/efficacy in HER2+ LM.

This study evaluates intrathecal/intra-Ommaya T-DXd plus systemic therapy in active HER2+ meningeal/brain metastases, assessing safety, intracranial efficacy, and CSF/peripheral blood T-DXd distribution to clarify BBB penetration potential. Findings may guide novel therapeutic strategies for this high-need population.

Read the detailed description

Multiple clinical trials have demonstrated the efficacy of systemic T-DXd in advanced HER2-expressing breast cancer with leptomeningeal and/or brain metastases. However, the median survival of leptomeningeal metastasis (LM) patients remains only 3-4 months, and treatment options for isolated brain metastases are limited, underscoring the need for more effective therapeutic strategies.

While systemic therapies have prolonged survival in advanced breast cancer, intracranial disease management remains constrained by a lack of effective local treatments. As the use of T-DXd increases, the progression of intracranial lesions in patients who have received prior local therapy or lack indications for radiotherapy has become a critical unmet clinical challenge.

Conventional understanding holds that large biologic molecules poorly penetrate the blood-brain barrier (BBB). Preclinical studies detected neither T-DXd nor free DXd (payload) in cerebrospinal fluid (CSF), and the distribution of T-DXd in human CSF remains uncharacterized. However, preliminary data suggest that intrathecal trastuzumab-alone or combined with pertuzumab-exhibits acceptable safety and efficacy in HER2-positive LM.

Correction Notice: The Study Start Date was initially listed as April 18, 2025 (the date of Ethics Committee approval). It has been corrected to May 12, 2025, which is the actual date of first participant enrollment.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years, regardless of gender.
  • -expressing advanced or breast cancer
  • Subjects with active only must have at least one intracranially (RANO-BM criteria).
  • Adequate organ and bone marrow function
  • No radiotherapy, chemotherapy, targeted therapy, immunotherapy, endocrine therapy, or surgery within 2 weeks prior to enrollment (or within 5 half-lives of prior therapy, whichever is shorter).
  • All prior treatment-related toxicities must have resolved to ≤Grade 1

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of other within the past 5 years, except for cured carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin, other in situ carcinomas, or papillary thyroid carcinoma.
  • Uncontrolled concurrent illnesses including, but not limited to: persistent or active infections, uncontrolled or cardiovascular diseases, severe chronic gastrointestinal disorders with diarrhea, or psychiatric/social conditions that may compromise compliance with study requirements, significantly increase AE risks, or impair the subject's ability to provide written .
  • History of (non-infectious) ILD/non-infectious pneumonitis requiring therapy, current ILD/non-infectious pneumonitis, or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging during screening.
  • Clinically significant pulmonary comorbidities
  • Use of or systemic corticosteroids (>10 mg/day prednisone equivalent) for immunosuppression within 2 weeks prior to first dose (excluding intranasal/inhaled corticosteroids).
  • Any active disease or history of autoimmune disease with potential recurrence.
  • Uncontrolled infections requiring IV antibiotics, antivirals, or antifungals.
  • Active primary immunodeficiency, known infection, active (HBsAg+ with HBV DNA ≥500 IU/mL) or infection. HCV antibody-positive subjects are eligible only if PCR confirms HCV RNA negativity.
  • Radiographic evidence of tumor encasement/invasion of major blood vessels, or investigator-determined high risk of fatal hemorrhage due to probable vascular invasion during treatment.
  • Pregnant/lactating women, or subjects of unwilling/unable to use effective .
  • Any other condition deemed by investigators to potentially affect trial conduct or outcome interpretation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
139 participants (estimated)

Study arms

  • Experimental
    Phase I/Arm A(Intrathecal Dose-Escalation Phase)

    Population : T-DXd-naïve subjects with leptomeningeal metastases (LM), with or without concurrent brain metastases (BM). Cycle 1 : Intrathecal (IT) T-DXd monotherapy to assess cerebrospinal fluid (CSF) and systemic pharmacokinetics (PK). Cycles 2+ : IT T-DXd combined with intravenous (IV) T-DXd in a dose-escalation design to determine the maximum tolerated dose (MTD) . DLT Evaluation : The first two cycles serve as the dose-limiting toxicity (DLT) observation window . Endpoint : The recommended Phase 2 dose (RP2D) will be determined by investigator assessment

    Drug: T-DXd

  • Experimental
    Phase I/Arm B(Systemic-to-Intrathecal Transition Phase)

    Population : T-DXd-naïve subjects with LM ± BM. Cycle 1 : IV T-DXd monotherapy to characterize CSF and systemic PK profiles. Cycles 2+ : IT administration of the RP2D of T-DXd combined with IV therapy

    Drug: T-DXd

  • Experimental
    Phase II/Arm A

    HER2-positive advanced breast cancer with progressive leptomeningeal and/or brain metastases after prior T-DXd therapy

    Drug: T-DXd

  • Experimental
    Phase II/Arm B

    HER2-low (IHC 1+ or 2+/ISH-) advanced breast cancer with progressive leptomeningeal and/or brain metastases after prior T-DXd therapy

    Drug: T-DXd

  • Experimental
    Phase II/Arm C

    HER2-positive advanced breast cancer with progressive brain metastases (without leptomeningeal involvement) after prior T-DXd therapy

    Drug: T-DXd

  • Experimental
    Phase II/Arm D

    HER2-low advanced breast cancer with progressive brain metastases (without leptomeningeal involvement) after prior T-DXd therapy

    Drug: T-DXd

  • Experimental
    Phase II/Arm E

    T-DXd-naïve HER2-positive advanced breast cancer with progressive leptomeningeal and/or brain metastases

    Drug: T-DXd

  • Experimental
    Phase II/Arm F

    T-DXd-naïve HER2-low advanced breast cancer with progressive leptomeningeal and/or brain metastases

    Drug: T-DXd

  • Experimental
    Phase II/Arm G

    T-DXd-naïve HER2-positive advanced breast cancer with progressive brain metastases (without leptomeningeal involvement)

    Drug: T-DXd

  • Experimental
    Phase II/Arm H

    T-DXd-naïve HER2-low advanced breast cancer with progressive brain metastases (without leptomeningeal involvement)

    Drug: T-DXd

Interventions

  • DrugTrastuzumab deruxtecanStudies of Trastuzumab deruxtecanTrastuzumab deruxtecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Evaluating safety and efficacy of intrathecal or ommaya reservoir administration of T-DXd in patients with HER2-expressing breast cancer with active leptomeningeal and/or brain metastases based on systemic therapy

    Also known as: DS8201a

06

What researchers measure

Primary outcomes

  1. Phase I Stage Cohort A: Maximum Tolerated Dose (MTD)

    Cohort A: Maximum Tolerated Dose (MTD) of intracapsular administration,In the dose increment stage, the highest dose whose estimated DLT rate is closest to the target DLT rate but does not exceed the upper bound of the equivalent interval of DLT rate is selected as MTD.

    Time frame: Up to 21 days after the first dose

  2. Phase I Stage Cohort B: Maximum serum concentration (Cmax)

    Cohort B: Maximum serum concentration (Cmax) of T-DXd in cerebrospinal fluid and blood will be investigated.

    Time frame: Up to 21 days after the first dose

  3. Phase I Stage Cohort B:Time to maximum serum concentration (Tmax)

    Cohort B: Time to maximum serum concentration (Tmax) of T-DXd in cerebrospinal fluid and blood will be investigated.

    Time frame: Up to 21 days after the first dose

  4. Phase I Stage Cohort B:Half-life (T1/2)

    Cohort B: Half-life (T1/2) of T-DXd in cerebrospinal fluid and blood will be investigated.

    Time frame: Up to 21 days after the first dose

  5. Phase II Stage Cohorts A: LM-OS

    Cohorts A: leptomeningeal metastasis-overall survival(LM-OS)

    Time frame: 18 months

  6. Phase II Stage Cohorts B: LM-OS

    Cohorts B: leptomeningeal metastasis-overall survival(LM-OS)

    Time frame: 18 months

  7. Phase II Stage Cohorts C: LM-ORR

    Cohorts C: leptomeningeal metastasis-Objective Response Rate(LM-ORR)

    Time frame: 18 months

  8. Phase II Stage Cohorts D: LM-ORR

    Cohorts D: leptomeningeal metastasis-Objective Response Rate(LM-ORR)

    Time frame: 18 months

  9. Phase II Stage Cohorts E: LM-OS

    Cohorts E: leptomeningeal metastasis-overall survival(LM-OS)

    Time frame: 18 months

  10. Phase II Stage Cohorts F: LM-OS

    Cohorts F: leptomeningeal metastasis-overall survival(LM-OS)

    Time frame: 18 months

  11. Phase II Stage Cohorts G: LM-ORR

    Cohorts G: leptomeningeal metastasis-Objective Response Rate(LM-ORR)

    Time frame: 18 months

  12. Phase II Stage Cohorts H: LM-ORR

    Cohorts H: leptomeningeal metastasis-Objective Response Rate(LM-ORR)

    Time frame: 18 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jan 2027, 20 months after the start.

Of 167 non-industry phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 95. This study's planned 20 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Apr 2025 → May 2025, primary completion Aug 2026 → Jan 2027 and completion Feb 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2025
First posted
Aug 21, 2025
StartActual
May 12, 2025was Apr 2025
Primary completionEst.
Jan 30, 2027was Aug 2026
CompletionEst.
Jun 28, 2027was Feb 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 18, 2025→May 12, 2025
Oct 26, 2026
Primary completion
Aug 30, 2026→Jan 30, 2027
Oct 26, 2026
Study completion
Feb 28, 2027→Jun 28, 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Start date Apr 18, 2025→May 12, 2025
    Primary completion Aug 30, 2026→Jan 30, 2027
    Study completion Feb 28, 2027→Jun 28, 2027
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07134153
Lead sponsor
Fudan University
Responsible party
Jian Zhang,MD (Director of Phase I Clinical Trial Department; Professor, Chief physician of oncology department, Fudan University) — Principal investigator
First posted
Aug 21, 2025
Start date
May 12, 2025
Primary completion
Jan 30, 2027 (estimated)
Completion
Jun 28, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Jian Zhang, MD, PhD
Contact
syner2000@163.com
+8664175590 ext. 85000
Yanchun Meng, MD
Contact
ycmclinicaltrials@126.com
+8664175590 ext. 63028

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion